Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
9.50
+1.25 (15.15%)
Jun 5, 2025, 2:44 PM EDT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
11.93
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
15.40B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
Innovent Biologics News
- 7 days ago - 2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer - PRNewsWire
- 8 days ago - ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma - PRNewsWire
- 11 days ago - Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies - PRNewsWire
- 21 days ago - Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation - PRNewsWire
- 4 weeks ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study ... - GuruFocus
- 4 weeks ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema - PRNewsWire
- 4 weeks ago - Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 - PRNewsWire
- 5 weeks ago - Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies - PRNewsWire